Short communication: High polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: Possible impact on enfuvirtide efficacy

AIDS Research and Human Retroviruses

Volumn 26, Issue 3, 2010, Pages 307-311

  Teixeira, Carla ^a   De Sá Filho, Dercy ^b   Alkmim, Wagner ^a   Janini, Luiz Mario ^a   Diaz, Ricardo Sobhie ^a   Komninakis, Shirley ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Plastic Surgery   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENFUVIRTIDE; GLYCOPROTEIN GP 41; PROTEINASE; PROTEINASE B; REVERSE TRANSCRIPTASE B; RNA; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG EFFICACY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; BRAZIL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; PEPTIDE FRAGMENTS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77950228238     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0297     Document Type: Article

References (28)

1. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, and Eron JJ Jr: HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40:34-40.
2. Deeks SG, Barbour JD, Grant RM, and Martin JN: Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-220.
3. Koletar SL, Williams PL, Wu J, et al.: Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis 2004;39:1500-1506.
4. Lohse N, Kronborg G, Gerstoft J, et al.: Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIVinfected patients: A Danish, population-based, 6-year follow-up study. Clin Infect Dis 2006;42:136-144.
5. Zaccarelli M, Tozzi V, Lorenzini P, et al.: Multiple drug classwide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-1089.
6. Baelen KV: HIV-1 susceptibility to the maturation inhibitor bevirimat is modulated by natural polymorphisms at positions 369-371 in Gag spacer peptide 1. Antiviral Ther 2008; 13:A30.
7. Sá-Filho DJS, Diaz RS, Munerato P, Brunstein A, Fusuma E, et al.: Analysis of full-length human immunodeficiency virus type 1 genome reveals a variable spectrum of subtypes B and F recombinants in Sao Paulo, Brazil. AIDS Res Hum Retroviruses 2005;21:145-151.
8. De Sa Filho DJ, Sucupira MC, Caseiro MM, Sabino EC, Diaz RS, and Janini LM: Identification of two HIV type 1 circulating recombinant forms in Brazil. AIDS Res Hum Retroviruses 2006;22:1-13.
9. Santos AF, Sousa TM, Soares EA, et al.: Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil. AIDS 2006;20:2011-2019.
10. Diaz RS, Sanabani S, Sucupira MCA, Tanuri A, Sabino EC, and Janini LMR: Selective regimes and evolutionary rates of HIV-1 subtype B V3 variants in the Brazilian epidemic. Virology 2008;381:184-193.
11. Medeiros R and Castelo A: Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis 2002;6:298-304.
12. Munerato P, Sucupira MC, Oliveiros MP, Souza DF, Pereira AA, Janini LM, Inocêncio, LA, and Diaz RS: HIV Type 1 antiretroviral resistance mutations in subtypes B, C, and F in the city of São Paulo, Brazil. AIDS Res Hum Retroviruses 2010;26:265-273.
13. Hanna SL, Yang C, Owen SM, and Lal RB: Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. AIDS 2002;16:1603-1608.
14. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
15. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
16. Menzo S, Castagna A, Monachetti A, et al.: Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004;48:3253-3259.
17. Rimsky LT, Shugars DC, and Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41- derived inhibitory peptides. J Virol 1998;72:986-993.
18. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
19. Xu L, Pozniak A, Wildfire A, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-1119.
20. Sista PR, Melby T, Davison D, et al.: Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-1794.
21. Perez-Alvarez L, Carmona R, Ocampo A, et al.: Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006;78: 141-147.
22. Si-Mohamed A, Piketty C, Tisserand P, et al.: Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007;44:1-5.
23. Kilby JM, Hopkins S, Venetta TM, et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4: 1302-1307.
24. Lu J, Deeks SG, Hoh R, et al.: Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60-64.
25. Rockstroh J, Dejesus E, Donatacci L, et al.: Adherence to enfuvirtide and its impact on treatment efficacy. AIDS Res Hum Retroviruses 2008;24:141-148.
26. Oliveira AC, Martins AN, Pires AF, et al.: Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART. AIDS Res Hum Retroviruses 2009;25:193-198.
27. Lalezari JP, Henry K, O'HearnM, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
28. Lazzarin A, Clotet B, Cooper D, et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.